Methylenetetrahydrofolate reductase polymorphism associated with moderate hyperhomocysteinaemia in a patient with livedo vasculopathy: Treatment with vitamin supplementation and low molecular weight heparin [8]

British Journal of Dermatology

Volumn 155, Issue 4, 2006, Pages 850-852

  Rampf, J ^a   Sunderkotter C ^a   Hirschfeld, G ^a   Scharffetter Kochanek, K ^a   Weiss, J M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PYRIDOXINE;

ADULT; CASE REPORT; CODON; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINAEMIA; LABORATORY TEST; LETTER; LIVEDO VASCULOPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN BIOPSY; ULCER; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; SKIN DISEASES, VASCULAR; VITAMINS;

EID: 33748452084     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07448.x     Document Type: Letter

References (10)

1. McCalmont CS, McCalmont TH, Jorizzo JL et al. Livedo vasculitis: vasculitis or thrombotic vasculopathy? Clin Exp Dermatol 1992; 17:4-8.
2. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407-13.
3. Gibson GE, Li H, Pittelkow MR. Homocysteinemia and livedoid vasculitis. J Am Acad Dermatol 1999; 40:279-81.
4. den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-62.
5. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111-13.
6. Calamia KT, Balabanova M, Perniciaro C et al. Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation. J Am Acad Dermatol 2002; 46:133-7.
7. Boyvat A, Kundakci N, Babikir MO et al. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 2000; 143:840-2.
8. Hairston BR, Davis MD, Gibson LE et al. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 2003; 139:987-90.
9. Stanger O, Herrmann W, Pietrzik K et al. DACH-LIGA Homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003; 41:1392-403.
10. Stanger O, Weger M, Renner W et al. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med 2001; 39:725-33.